| More than one hundred monoclonal antibodies (McAbs) have been established since koprowski et al. reported on the preparation of an anti-melanoma McAb and these promising developments have ushered in a brand new era in the scientific study, prevention and treatment of cancer. In 1980, McAbs were first employed in clinical trial for treatment of cancer in the United States and, in 1983, Miller et al. reported on the first successful case of lymphoma that was cured with McAbs. Thereafter, McAbs have been widely used in serodiagnosis, immunoimaging localization and targeted treatment of cancer. However, there still remains a controversial problem, that is, the selection of McAbs, which involves many important biological properties, including binding specificity, immunoreactivity , affinity, expression and modulation of appropriate antigens, and specific localization of McAbs on targeting cells through various in vivo barriers. Therefore, it is of great clinical significance to study these biological properties...
|
PDF Full Text Request